Oculis Holding AG (OCS) Cash from Financing Activities (2022 - 2026)
Oculis Holding AG (OCS) posted quarterly Cash from Financing Activities of $30.1 million for Q1 2026, down 73.9% year-over-year from $115.5 million in Q1 2025, and down 71.39% quarter-over-quarter from $105.3 million in Q4 2025.
Oculis Holding AG (OCS) Cash from Financing Activities (2022 - 2026) Analysis & Trends
Oculis Holding AG's Cash from Financing Activities history runs 5 years deep, the most recent figure standing at $30.1 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 73.9% year-over-year to $30.1 million; the TTM figure through Mar 2026 stood at $134.1 million (down 23.41% YoY), while the FY2025 annual figure was $225.4 million, up 267.45% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $30.1 million, down from $105.3 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $115.5 million in Q1 2025, with the low at -$2.1 million in Q3 2025.
- The 5-year median for Cash from Financing Activities is $2.0 million (2022), against an average of $30.2 million.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities plunged 264.05% in 2024, then jumped 58848.04% in 2025.
- Oculis Holding AG's Cash from Financing Activities stood at -$288570.1 in 2022, then jumped by 264.08% to $473488.9 in 2023, then jumped by 549.73% to $3.1 million in 2024, then jumped by 3324.12% to $105.3 million in 2025, then sank by 71.39% to $30.1 million in 2026.
- Business Quant data shows OCS's Cash from Financing Activities at $30.1 million in Q1 2026, $105.3 million in Q4 2025, and -$2.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - | 31.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.67 Mn |
| Jun 30, 2026 | 31.67 Mn |
| Mar 31, 2026 | 30.14 Mn |
| Mar 31, 2026 | 30.14 Mn |
| Dec 31, 2025 | 105.34 Mn |
| Dec 31, 2025 | 105.34 Mn |
| Sep 30, 2025 | -2.14 Mn |
| Sep 30, 2025 | -2.14 Mn |
| Jun 30, 2025 | 730,773.59 |
| Jun 30, 2025 | 730,773.59 |
| Mar 31, 2025 | 115.49 Mn |
| Mar 31, 2025 | 115.49 Mn |
| Dec 31, 2024 | 3.08 Mn |
| Dec 31, 2024 | 3.08 Mn |
| Sep 30, 2024 | -850,650.74 |
| Sep 30, 2024 | -850,650.74 |
| Jun 30, 2024 | 57.33 Mn |
| Jun 30, 2024 | 57.33 Mn |
| Mar 31, 2024 | 195,911.68 |
| Mar 31, 2024 | 195,911.68 |